clinical trial · NCT06351150
Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·phase3·recruiting·n = 214
Vasodilatory ShockAngiotensin II Injection0.9% sodium chloride injection
brief summary
A randomized, double-blind, placebo-controlled study on the treatment of refractory distributed shock with angiotensin II injection, with a random ratio of 1:1. Assuming a success rate of 25% for the main therapeutic endpoint in the control group and 50% for the experimental group, a total of 214 subjects will be enrolled, including 107 in the experimental group and 107 in the control group.
started
Jul 23, 2024
primary completion
Jun 1, 2027
completion
Dec 1, 2027
last updated
Jan 23, 2025
official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial to Evaluate the Efficacy and Safety of Angiotensin II Injection in the Background Treatment of Catecholamines and Other Vasopressors in Chinese Adult Patients With Refractory Distributive Shock
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol